Insulin resistance and β-cell dysfunction and the relationship with cardio-metabolic disorders among women with polycystic ovary syndrome

2018 ◽  
Vol 89 (6) ◽  
pp. 779-788 ◽  
Author(s):  
Liangshan Mu ◽  
Yue Zhao ◽  
Yuchen Lai ◽  
Rong Li ◽  
Jie Qiao
Keyword(s):  
Insulin Resistance ◽  
Polycystic Ovary Syndrome ◽  
Metabolic Disorders ◽  
Polycystic Ovary ◽  
Β Cell ◽  
Ovary Syndrome ◽  
Cell Dysfunction ◽  
The Relationship

Adiposity and metabolic dysfunction in polycystic ovary syndrome

2015 ◽  
Vol 21 (2) ◽  
Author(s):  
Susan Sam
Keyword(s):  
Insulin Resistance ◽  
Adipose Tissue ◽  
Polycystic Ovary Syndrome ◽  
Metabolic Disorders ◽  
Polycystic Ovary ◽  
Reproductive Age ◽  
Metabolic Dysfunction ◽  
Obese Women ◽  
Ovary Syndrome ◽  
Insulin Resistant

AbstractPolycystic ovary syndrome (PCOS) is the most common hormonal disorder among reproductive-age women and is associated with a high risk for metabolic disorders. Adiposity and insulin resistance are two prevalent conditions in PCOS and the likely culprits for the heightened metabolic risk. Up to 60% of women with PCOS are considered to be overweight or obese, and even among non-obese women with PCOS there is an increased accumulation of adipose tissue in abdominal depots. Insulin resistance in PCOS is unique and independent of obesity, as even non-obese women with this condition are frequently insulin resistant. However, obesity substantially aggravates the insulin resistance and the metabolic and reproductive abnormalities in women with PCOS. Recently, it has been shown that many aspects of adipose tissue function in PCOS are abnormal, and these abnormalities likely predispose to development of insulin resistance even in the absence of obesity. This review provides an overview of these abnormalities and their impact on development of metabolic disorders. At the end, an overview of the therapeutic options for management of adiposity and its complications in PCOS are discussed.

scholarly journals Specificities of the treatment for polycystic ovary syndrome and metabolic syndrome

2020 ◽  
Vol 3 (4) ◽  
pp. 254-259
Author(s):  
I.Yu. Il’ina ◽  
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Polycystic Ovary Syndrome ◽  
Metabolic Disorders ◽  
Negative Impact ◽  
Polycystic Ovary ◽  
Cardiovascular Complications ◽  
Polycystic Ovaries ◽  
Ovary Syndrome ◽  
Psychic Disorders

This paper discusses polycystic ovary syndrome (PCOS), a common endocrine disorder characterized by hirsutism, anovulation, and polycystic ovaries. Insulin resistance which is considered the major causative factor for both PCOS and metabolic syndrome is emphasized. The early diagnosis of metabolic disorders which increase the risk of cardiovascular complications and the complications of pregnancy (including gestational diabetes and hypertension which may result in preeclampsia and placental abruption) is of particular importance. The presence of metabolic syndrome in PCOS is associated with poor prognosis in terms of fertility and has a negative impact on the outcomes of in vitro fertilization in infertile women with PCOS. When describing treatment approaches, the role of metformin, inositol, folates, vitamin D, and statins in treating metabolic disorders in PCOS and metabolic syndrome, reducing the risks of cardiovascular complications, and realizing fertile function is highlighted. The course of PCOS is complicated by psychic disorders (i.e., depression, anxiety, bipolar disorder, or eating disorders) which are common in these women and should be considered when prescribing medications. KEYWORDS: polycystic ovary syndrome, insulin resistance, infertility, metabolic syndrome, cardiovascular complications, inositol, folates. FOR CITATION: Il’ina I.Yu. Specificities of the treatment for polycystic ovary syndrome and metabolic syndrome. Russian Journal of Woman and Child Health. 2020;3(4):254–259. DOI: 10.32364/2618-8430-2020-3-4-254-259.

scholarly journals The Relationship Between Insulin Resistance and Obesity and Serum Anti-mullerian Hormone Level in Chinese Women With Polycystic Ovary Syndrome: A Case-control Study.

2021 ◽  
Author(s):  
Han Zhao ◽  
Dexin Zhou ◽  
Cong Liu ◽  
Le Zhang
Keyword(s):  
Insulin Resistance ◽  
Linear Regression ◽  
Polycystic Ovary Syndrome ◽  
Multiple Linear Regression ◽  
Polycystic Ovary ◽  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Hormone Binding ◽  
Ovary Syndrome ◽  
The Relationship

Abstract BackgroundAnti-Mullerian Hormone (AMH) has an important role in the pathophysiological process of polycystic ovary syndrome (PCOS) by regulating follicular development and is closely related to the severity of PCOS. Previous studies have suggested that AMH levels in PCOS is related to hyperandrogenemia levels and are affected by obesity and insulin resistance. however, the exact relationship between AMH levels and obesity and insulin resistance remains unclear. We aimed to elucidate the relationship between insulin resistance and obesity and serum AMH levels in women with PCOS. MethodsWe conducted a retrospective study of 220 women with PCOS who had undergone an assortment of physical, endocrine, and metabolic assessments. AMH levels and various other indicators of PCOS in patients with different body mass indices (BMI) and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) levels were compared. Independent sample t-tests were performed to compare two groups. Pearson correlation analysis was performed to study the correlation between AMH and age, obesity, IR, and other indicators of PCOS, and multiple linear regression analysis was performed to determine the factors influencing AMH. Bilateral tests were performed for all statistical tests. The data were analysed using SPSS v25.0. Statistical significance was defined as a two-sided P-value of less than 0.05.ResultsWe found that >50% of patients with PCOS had insulin resistance, obesity, hyperandrogenemia, and abnormal glucose tolerance. AMH, testosterone (T), and HOMA-IR levels were affected by age, and older participants had lower AMH, HOMA-IR, and androgen levels (P < 0.05). Glycated hemoglobin levels were higher and AMH, luteinizing hormone (LH)/follicle-stimulating hormone (FSH), and LH levels were lower in non-obese individuals than in obese individuals (both P < 0.05). Participants in the non-insulin resistant (IR; NIR) group were older than those in the IR group (P < 0.05). AMH, LH, LH/FSH, and T levels in the IR group were significantly higher than those in the NIR group (P < 0.05). AMH levels were positively correlated with LH, LH/FSH, T, fasting insulin (FINS), and HOMA-IR levels as well as the free androgen index and negatively correlated with age, BMI, and sex hormone binding globulin levels (P < 0.05). Through multiple linear regression, we found that AMH levels could be explained by T, LH/FSH, FINS, sex hormone binding globulin, LH levels, and BMI.ConclusionsSerum AMH levels were closely related to metabolic abnormalities in PCOS. In patients with PCOS, AMH levels were positively correlated with HOMA-IR levels and negatively correlated with BMI. Thus, AMH combined with BMI and HOMA-IR levels could help determine the severity of PCOS.

Sign in / Sign up

Export Citation Format

Share Document